跨国药企中国两条腿走路：加速全球引进 与本土创新药一起出海

Core Insights - The rapid development of China's biopharmaceutical sector has prompted multinational pharmaceutical companies (MNCs) to adjust their strategies, focusing on increased investment in the Chinese market and accelerating the introduction of global innovative products into China [1][2] - MNCs are adopting a dual strategy of enhancing local market engagement while leveraging Chinese innovations to expand globally [1][2] Group 1: MNC Strategies in China - GSK's strategy emphasizes China as a source of innovation and aims to establish it as a global innovation center [1][4] - The CEO of Kelsey Group highlighted three strategic focuses: increasing investment in China, accelerating the introduction of global innovations, and integrating Chinese innovations into the global system [1][2] - The collaboration between Hengrui Medicine and GSK aims to develop up to 12 innovative drugs, with GSK committing a total of $500 million in upfront payments and potential milestone payments of approximately $12 billion [2][3] Group 2: Market Dynamics and Collaborations - China has become the second-largest source of projects for the top 20 MNCs, with a total of $39.4 billion in innovative drug assets introduced from January to August 2025, accounting for 37.4% of global transaction volume [2] - The license-out total for Chinese innovative drugs reached $92.03 billion in the first three quarters of 2025, indicating a surge in BD transactions [2] - Kelsey Group's partnership with Haisco for the innovative drug HSK31858 represents a significant step in pushing Chinese innovations to a global audience [4][5] Group 3: Investment and Growth in China - Kelsey Group reported a 22% revenue growth in the Chinese market for the 2024 fiscal year, with a 30% increase in local staff over the past two years [7][9] - The company aims to include China in early-stage global clinical trials to expedite the launch of innovative drugs [7] - Boehringer Ingelheim plans to invest over 5 billion RMB in R&D in China over the next five years, focusing on metabolic, inflammatory, eye health, and oncology areas [9] Group 4: Importance of Trade Shows - The China International Import Expo (CIIE) serves as a crucial platform for MNCs to showcase innovations and foster partnerships [8][9] - GSK and Boehringer Ingelheim utilize CIIE to launch new products and enhance their visibility in the Chinese market [9][10] - GSK's innovative drug, New Kela, exemplifies the successful transition from exhibition to market, receiving regulatory approval shortly after its debut at CIIE [10]